228 patents
Page 2 of 12
Utility
Varicella Zoster Virus (VZV) Vaccine
29 Dec 22
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella
Filed: 30 Apr 21
Utility
Carbonate Containing Lipid Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
29 Dec 22
The disclosure features novel lipids and compositions involving the same.
Kerry E. BENENATO, Souvik BISWAS, Mark CORNEBISE, Edward HENNESSY, Ellalahewage S. KUMARASINGHE
Filed: 18 Sep 20
Utility
Human Cytomegalovirus Vaccine
22 Dec 22
Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
Filed: 14 Jun 22
Utility
Polynucleotides Encoding Uridine Diphosphate Glycosyltransferase 1 Family, Polypeptide A1 for the Treatment of Crigler-najjar Syndrome
22 Dec 22
This disclosure relates to mRNA therapy for the treatment of Crigler-Najjar Syndrome Type 1 (CN-1). mRNAs for use in the invention, when administered in vivo, encode uridine diphosphate glycosyltransferase 1 family, polypeptide A1 (UGT1A1). mRNA therapies of the disclosure increase and/or restore deficient levels of UGT1A1 expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of bilirubin associated with deficient UGT1A1 activity in subjects.
Paolo G. V. Martini, Vladimir Presnyak
Filed: 13 Sep 19
Utility
Sterol Analogs and Uses Thereof
22 Dec 22
The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.
Kerry BENENATO, Mark CORNEBISE, Edward J. HENNESSY
Filed: 19 Sep 19
Utility
Terminally Modified Rna
15 Dec 22
The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
Tirtha CHAKRABORTY, Stephane BANCEL, Stephen G. HOGE, Atanu ROY, Antonin DE FOUGEROLLES, Noubar B. AFEYAN
Filed: 18 Dec 20
Utility
Lipid nanoparticle compositions and methods of formulating the same
13 Dec 22
Provided herein are compositions and methods of reducing adduct formation.
Meredith Packer, Dipendra Gyawali, Serenus Hua, Gabor Butora, Gregory John Mercer
Filed: 22 Oct 21
Utility
Messenger Rna Comprising Functional Rna Elements and Uses Thereof
8 Dec 22
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide desirable regulation of mRNA localization, stability, and/or translation to yield increased mRNA expression and activity of an encoded polypeptide.
Ruchi JAIN, David REID, Vladimir PRESNYAK, Alicia BICKNELL, Caroline KÖHRER
Filed: 24 Jun 20
Utility
HMPV Mrna Vaccine Composition
1 Dec 22
Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
Filed: 5 May 22
Utility
Methods of Using OX40 Ligand Encoding Polynucleotides
1 Dec 22
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. FREDERICK, Ailin BAI
Filed: 6 Jul 22
Utility
Compounds and Compositions for Intracellular Delivery of Therapeutic Agents
1 Dec 22
The disclosure features novel lipids and compositions involving the same.
Kerry E. BENENATO, Mark CORNEBISE
Filed: 30 Nov 21
Utility
Stabilized Formulations
24 Nov 22
Stabilized formulations of nucleic acids, including lipid nanoparticle formulations which encapsulate nucleic acids, are provided.
Edward J. Hennessy
Filed: 22 Apr 22
Utility
Polynucleotides Encoding Methylmalonyl-coa Mutase for the Treatment of Methylmalonic Acidemia
24 Nov 22
This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.
Tal Zaks, Kelly Lindert, Lin Tung Guey
Filed: 8 May 20
Utility
Polynucleotides encoding methylmalonyl-CoA mutase
22 Nov 22
The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof.
Paolo Martini, Vladimir Presnyak, Kerry Benenato, Stephen Hoge, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe
Filed: 18 Jul 19
Utility
Zoonotic disease RNA vaccines
15 Nov 22
Provide herein are Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 22 Jan 21
Utility
Human Cytomegalovirus Vaccine
3 Nov 22
Aspects of the invention relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines comprising hCMV antigenic polypeptides gH, gL, UL128, UL130, UL131 A and gB formulated in lipid nanoparticles, wherein the antigen-specific immune response to hCMV results in neutralizing antibodies that have i) a geometric mean titer of at least 3-fold against epithelial cell infection or ii) a geometric mean ratio of 9-41 against epithelial cell infection or iii) a geometric mean ratio of 4-8-fold against fibroblast infection.
Lori Panther, Shinu John, Tal Zaks
Filed: 11 Sep 20
Utility
Processes for Purifying Downstream Products of In Vitro Transcription
3 Nov 22
Provided herein, in some embodiments, are methods of purifying low-salt RNA compositions using denaturing oligo-dT chromatography.
Michael Shamashkin, Matthew Scott, Peter Wojciechowski
Filed: 13 Aug 20
Utility
Human cytomegalovirus RNA vaccines
1 Nov 22
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
Filed: 27 Mar 20
Utility
RNA polymerase variants for co-transcriptional capping
1 Nov 22
The present disclosure provides RNA polymerase variants for high efficiency transcription.
Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
Filed: 20 May 21
Utility
Modified messenger RNA comprising functional RNA elements
1 Nov 22
The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
Filed: 18 May 18